HTEC Robo Global Healthcare Technology And Innovation Etf
- 28.925
- +0.053+0.18%
BTIG Sticks to Their Buy Rating for Guardant Health (GH)
Buy Rating Affirmed for Guardant Health Amid Positive FDA Approval and Growth Prospects
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY), PTC Therapeutics (PTCT) and Tectonic Therapeutic (TECX)
Canaccord Genuity Maintains Sell on Vertex Pharmaceuticals, Raises Price Target to $376
Vertex Pharmaceuticals Analyst Ratings
CCORF Maintains Vertex Pharmaceuticals(VRTX.US) With Sell Rating, Raises Target Price to $376
Guardant Health Analyst Ratings
BofA Securities Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $40
Baird Adjusts Price Target on Revvity to $136 From $127
A Quick Look at Today's Ratings for Revvity(RVTY.US), With a Forecast Between $125 to $145
Canaccord Genuity Adjusts Price Target on Vertex Pharmaceuticals to $376 From $371
Revvity Price Target Raised to $125.00/Share From $115.00 by Barclays
CCORF Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $42
TD Cowen Sticks to Their Buy Rating for Guardant Health (GH)
TD Cowen Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $41
Piper Sandler Maintains Illumina(ILMN.US) With Buy Rating, Maintains Target Price $200
Guardant Health Poised for Growth: Buy Rating Affirmed Amid FDA Approval and Strategic Expansions
Revvity's Balanced Performance Amidst Market Challenges: A Hold Recommendation With Updated Price Objective
BofA Securities Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $40
Barclays Sticks to Their Hold Rating for Revvity (RVTY)